Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Idebenone for primary progressive multiple sclerosis
BTG Commences Phase IIa Study of Multiple Sclerosis
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Unusual case of gastroparesis leading to severe gastromegaly with demyelinating disease as a rare cause.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Disease-modifying treatments for progressive multiple sclerosis.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Copolymer 1 inhibits manifestations of graft rejection.
Ustekinumab.
Extoxnet (extension toxicology network), 4-aminopyridine
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Changes to anti-JCV antibody levels in a Swedish national MS cohort.

Pages